The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.
Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
To develop the test, the firm said it used a library of MRSA strains collected around the world, and included components that reduce false positive results.
The evidence-based guidelines for testing individuals at risk of latent or active TB infection include recommendations on interferon-gamma release and molecular assays.
Cepheid noted that the cartridge is not currently part of its five-year commercial plan, but the firm is in discussions with outside parties to push development forward.
Cepheid is now an indirect wholly owned subsidiary of Danaher, and the firm's stock will no longer be traded on the Nasdaq.
The firm, which is in the process of being acquired by Danaher, reported strong revenue growth for both its consumables and systems.
The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.
The test is the first in a proposed line of assays that will run on the GeneXpress platform with run times of around 30 minutes.
Startup companies are taking on personalized medicine, CNET reports.
Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.
The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.
In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.